FERRO, MATTEO
 Distribuzione geografica
Continente #
AS - Asia 14.513
EU - Europa 13.177
NA - Nord America 12.125
SA - Sud America 1.758
AF - Africa 384
OC - Oceania 103
Continente sconosciuto - Info sul continente non disponibili 8
Totale 42.068
Nazione #
US - Stati Uniti d'America 11.627
DE - Germania 5.943
SG - Singapore 4.637
CN - Cina 4.344
IT - Italia 2.280
HK - Hong Kong 1.447
BR - Brasile 1.375
BD - Bangladesh 1.182
GB - Regno Unito 1.107
VN - Vietnam 1.083
RU - Federazione Russa 998
FR - Francia 648
SE - Svezia 619
IN - India 586
NL - Olanda 320
IE - Irlanda 287
FI - Finlandia 278
CA - Canada 266
ID - Indonesia 214
CI - Costa d'Avorio 193
JP - Giappone 179
KR - Corea 154
AR - Argentina 139
ES - Italia 138
TR - Turchia 124
MX - Messico 116
AU - Australia 96
AT - Austria 82
IQ - Iraq 79
PL - Polonia 69
DK - Danimarca 68
EC - Ecuador 62
PH - Filippine 59
PK - Pakistan 58
UA - Ucraina 55
ZA - Sudafrica 55
CO - Colombia 52
BE - Belgio 49
SA - Arabia Saudita 45
CH - Svizzera 41
IL - Israele 39
MA - Marocco 38
IR - Iran 34
CL - Cile 32
PT - Portogallo 31
EG - Egitto 28
MY - Malesia 28
VE - Venezuela 28
PY - Paraguay 27
AE - Emirati Arabi Uniti 26
TW - Taiwan 26
JM - Giamaica 22
PE - Perù 22
UZ - Uzbekistan 22
TH - Thailandia 21
TT - Trinidad e Tobago 20
CR - Costa Rica 19
RO - Romania 19
KE - Kenya 18
JO - Giordania 17
AL - Albania 16
CZ - Repubblica Ceca 16
NP - Nepal 14
GR - Grecia 13
KZ - Kazakistan 13
OM - Oman 13
TN - Tunisia 12
AZ - Azerbaigian 11
BO - Bolivia 11
EE - Estonia 11
DZ - Algeria 10
GT - Guatemala 9
HR - Croazia 9
NO - Norvegia 9
UY - Uruguay 9
DO - Repubblica Dominicana 8
HU - Ungheria 8
LT - Lituania 8
LU - Lussemburgo 8
RS - Serbia 8
CY - Cipro 7
KG - Kirghizistan 7
LB - Libano 7
MK - Macedonia 7
SK - Slovacchia (Repubblica Slovacca) 7
AM - Armenia 6
BH - Bahrain 6
ET - Etiopia 6
HN - Honduras 6
LV - Lettonia 6
NI - Nicaragua 6
PA - Panama 6
PS - Palestinian Territory 6
BG - Bulgaria 5
BY - Bielorussia 5
NZ - Nuova Zelanda 5
SV - El Salvador 5
A2 - ???statistics.table.value.countryCode.A2??? 4
AO - Angola 4
LA - Repubblica Popolare Democratica del Laos 4
Totale 42.002
Città #
Frankfurt am Main 5.493
Dallas 2.248
Singapore 2.097
Ashburn 1.624
Hong Kong 1.063
San Jose 978
Hefei 957
Southend 773
Council Bluffs 575
Milan 566
Beijing 558
Chandler 431
Los Angeles 425
Ho Chi Minh City 347
New York 326
Lauterbourg 317
Bengaluru 304
Dublin 281
Fairfield 279
Santa Clara 277
Buffalo 276
Moscow 250
Hanoi 241
Seattle 233
Guangzhou 226
Princeton 202
Abidjan 193
Houston 193
Wilmington 164
Rome 158
Helsinki 155
Jakarta 145
Boardman 131
São Paulo 131
Naples 119
Cambridge 118
Tokyo 116
Woodbridge 114
Shanghai 109
Seoul 105
Ann Arbor 98
Munich 91
Chicago 87
Shenzhen 81
Des Moines 77
Phoenix 76
Istanbul 72
London 69
Lappeenranta 68
Toronto 68
Columbus 67
Nanjing 67
Tianjin 66
Cangzhou 64
Berlin 56
Montreal 56
Nuremberg 55
Turin 53
Atlanta 52
Orem 52
Amsterdam 51
Jinan 48
Hyderabad 45
Washington 45
Dearborn 44
Vienna 44
Haiphong 42
Changsha 41
Bari 40
Da Nang 40
Rio de Janeiro 40
Shenyang 37
Brooklyn 36
The Dalles 35
Bologna 34
Düsseldorf 33
Hangzhou 33
San Diego 33
Warsaw 32
Baghdad 31
Brussels 31
Mumbai 31
Redwood City 31
Wuhan 31
Zhengzhou 31
Curitiba 30
Turku 30
Brasília 29
Denver 29
Florence 29
Mexico City 29
Salvador 28
Tel Aviv 28
Biên Hòa 27
Palermo 27
Johannesburg 26
Paris 26
Silver Spring 26
Sydney 26
Catania 25
Totale 26.027
Nome #
Perioperative outcomes of robotic and laparoscopic simple prostatectomy: a European-American multi-institutional analysis 648
Overview of potential determinants of radical prostatectomy versus radiation therapy in management of clinically localized prostate cancer: results from an Italian, prospective, observational study (the Pros-IT CNR study) 582
A biofeedback-guided programme or pelvic floor muscle electric stimulation can improve early recovery of urinary continence after radical prostatectomy: A meta-analysis and systematic review 525
A novel nomogram to identify candidates for active surveillance among patients with ISUP Grade Group 1 or ISUP Grade Group 2 prostate cancer, according to multiparametric magnetic resonance imaging findings 475
Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: The Pros-IT CNR study 392
Advanced Age Impacts Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma 352
Repeated MRIs during Active Surveillance: natural history of prostatic lesions and upgrading rates 344
Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG 331
Multiparametric magnetic resonance imaging and frozen-section analysis efficiently predict upgrading, upstaging, and extraprostatic extension in patients undergoing nerve-sparing robotic-assisted radical prostatectomy 321
Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml 298
Increased Body Mass Index Is a Risk Factor for Poor Clinical Outcomes after Radical Prostatectomy in Men with International Society of Urological Pathology Grade Group 1 Prostate Cancer Diagnosed with Systematic Biopsies 294
CyberKnife Ultra-Hypofractionated SBRT for Localized Prostate Cancer with Dose Escalation to the Dominant Intraprostatic Lesion: In Silico Planning Study 293
Long non-coding RNA containing ultraconserved genomic region 8 promotes bladder cancer tumorigenesis 286
Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma 277
Impact of alcohol consumption on the risk of developing bladder cancer: a systematic review and meta-analysis 262
Long-term follow‐up outcomes after percutaneous us/ct‐guided radiofrequency ablation for ct1a‐b renal masses : Experience from single high‐volume referral center 262
Chronic bacterial prostatitis : efficacy of short-lasting antibiotic therapy with prulifloxacin (Unidrox®) in association with saw palmetto extract, lactobacillus sporogens and arbutin (Lactorepens®) 256
Correction: Confirmatory multiparametric magnetic resonance imaging at recruitment confers prolonged stay in active surveillance and decreases the rate of upgrading at follow-up (Prostate Cancer and Prostatic Diseases, (2020), 23, 1, (94-101), 10.1038/s41391-019-0160-3) 256
A novel nomogram predicting lymph node invasion among patients with prostate cancer: The importance of extracapsular extension at multiparametric magnetic resonance imaging 255
New cross-talk layer between ultraconserved non-coding RNAs, microRNAs and polycomb protein YY1 in bladder cancer 253
A comprehensive evaluation of sexual and reproductive outcomes following robot-assisted retroperitoneal lymph node dissection for nonseminomatous germ cell tumor 252
Therapeutic Sequences in the Treatment of High-Risk Prostate Cancer: Paving the Way Towards Multimodal Tailored Approaches 251
Robot assisted radical prostatectomy in kidney transplant recipients: surgical, oncological and functional outcomes of two different robotic approaches 248
Confirmatory multiparametric magnetic resonance imaging at recruitment confers prolonged stay in active surveillance and decreases the rate of upgrading at follow-up 246
Pathological findings at radical prostatectomy of biopsy naïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling 244
Neutrophil, platelets, and eosinophil to lymphocyte ratios predict gleason score upgrading in low-risk prostate cancer patients 242
Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice 235
Robot-assisted intracorporeal orthotopic ileal neobladder : Description of the “shell” technique 233
Bladder preservation in non-metastatic muscle-invasive bladder cancer (MIBC): a single-institution experience 232
Surgical blood loss during holmium laser enucleation of the prostate (HoLEP) is not affected by short-term pretreatment with dutasteride: A double-blind placebo-controlled trial on prostate vascularity 231
Penile-Sparing Surgery for Tumour Recurrence after Previous Glansectomy/Partial Penectomy: Treatment Feasibility and Oncological Outcomes 229
Predictors of residual T1 high grade on re-transurethral resection in a large multi-institutional cohort of patients with primary T1 high-grade/grade 3 bladder cancer 228
Impact of Surgical Approach on Patient-Reported Outcomes after Radical Prostatectomy: A Propensity Score-Weighted Analysis from a Multicenter, Prospective, Observational Study (The Pros-IT CNR Study) 228
Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol 228
High-throughput detection of low abundance sialylated glycoproteins in human serum by TiO 2 enrichment and targeted LC-MS/MS analysis: application to a prostate cancer sample set 228
Body mass index was associated with upstaging and upgrading in patients with low-risk prostate cancer who met the inclusion criteria for active surveillance 227
How Can the COVID-19 Pandemic Lead to Positive Changes in Urology Residency? 220
Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer 219
Improving the prediction of pathologic outcomes in patients undergoing radical prostatectomy : the value of prostate cancer antigen 3 (PCA3), prostate health index (Phi) and sarcosine 218
Clinical evaluation and disease management of PI-RADS 3 lesions. Analysis from a single tertiary high-volume center 218
Predicting Peri-Operative Outcomes in Patients Treated with Percutaneous Thermal Ablation for Small Renal Masses: The SuNS Nephrometry Score 217
Impact of uni- or multifocal perineural invasion in prostate cancer at radical prostatectomy 217
An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer 213
Beyond PSA : The role of prostate health index (phi) 212
Artificial intelligence and radiomics in evaluation of kidney lesions: a comprehensive literature review 210
Thulium–yttrium–aluminium–garnet (Tm:YAG) laser treatment of penile cancer: oncological results, functional outcomes, and quality of life 209
MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohort 209
Robot-assisted nephroureterectomy: surgical and mid-term oncological outcomes in over 1100 patients (ROBUUST 2.0 collaborative group) 205
Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy 204
Sexual function recovery after robot-assisted radical prostatectomy : outcomes from an Italian referral centre and predicting nomogram 203
Adding systematic biopsy to magnetic resonance ultrasound fusion targeted biopsy of the prostate in men with previous negative biopsy or enrolled in active surveillance programs: A prospective single center, randomized study 203
Artificial Intelligence in the Advanced Diagnosis of Bladder Cancer-Comprehensive Literature Review and Future Advancement 202
Postoperative vacuum therapy following AMS™ LGX 700® inflatable penile prosthesis placement: penile dimension outcomes and overall satisfaction 200
Virtue male sling for post-prostatectomy stress incontinence : a prospective evaluation and mid-term outcomes 199
SARS-CoV-2 Infection and High-Risk Non-Muscle-Invasive Bladder Cancer: Are There Any Common Features 198
Robot-Assisted, Laparoscopic, and Open Radical Cystectomy: Pre-Operative Data of 1400 Patients From The Italian Radical Cystectomy Registry 197
Circulating preoperative testosterone level predicts unfavourable disease at radical prostatectomy in men with International Society of Urological Pathology Grade Group 1 prostate cancer diagnosed with systematic biopsies 197
First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings 197
Robot-Assisted Radical Cystectomy for Nonmetastatic Urothelial Carcinoma of Urinary Bladder: A Comparison between Intracorporeal Versus Extracorporeal Orthotopic Ileal Neobladder 195
Predicting positive surgical margins in partial nephrectomy : A prospective multicentre observational study (the RECORd 2 project) 194
The impact of sars-cov-2 pandemic on time to primary, secondary resection and adjuvant intravesical therapy in patients with high-risk non-muscle invasive bladder cancer: A retrospective multi-institutional cohort analysis 194
Modified glasgow prognostic score is associated with risk of recurrence in bladder cancer patients after radical Cystectomy : a multicenter experience 191
Predicting Pathological Features at Radical Prostatectomy in Patients with Prostate Cancer Eligible for Active Surveillance by Multiparametric Magnetic Resonance Imaging 190
Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma 189
Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis 188
Outcomes of Partial and Radical Nephrectomy in Octogenarians – A Multicenter International Study (Resurge) 185
Increased expression of the autocrine motility factor is associated with poor prognosis in patients with clear cell-renal cell carcinoma 184
Insertion of a testicular prosthesis at the time of radical orchiectomy for testicular cancer is safe in patients who will subsequently undergo chemotherapy or radiotherapy 184
Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette-Guerin Immunotherapy 183
Thermal ablation for small renal masses: Identifying the most appropriate tumor size cut-off for predicting perioperative and oncological outcomes 183
Oligometastatic Prostate Cancer: A Comparison between Multimodality Treatment vs. Androgen Deprivation Therapy Alone 180
Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer 178
Penile-sparing surgery for patients with superficial or initially invasive squamous cell carcinoma of the penis : long-term oncological outcomes 177
A guide for oncologic patient management during covid-19 pandemic: The initial experience of an Italian oncologic hub with exemplificative focus on uro-oncologic patients 176
Impact of the COVID-19 pandemic on urological cancers: The surgical experience of two cancer hubs in London and Milan 173
Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis 172
Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancer 170
A Phase 3 Prospective Randomized Trial to Evaluate the Impact of Augmented Reality During Robot-assisted Radical Prostatectomy on the Rates of Postoperativane Surgical Margins: A Clinical Trial Protocol 170
Meta-analysis of studies comparing oncologic outcomes of radical prostatectomy and brachytherapy for localized prostate cancer 170
What is the best time for postoperative radiation therapy in pN1 prostate cancer? 169
Third-Line chemotherapy for metastatic Urothelial Cancer : a retrospective observational study 169
Dysregulated metabolism : a relevant player in prostate cancer progression and clinical management 169
A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy 168
The stress hormone norepinephrine increases migration of prostate cancer cells in vitro and in vivo 168
Changes in renal function after nephroureterectomy for upper urinary tract carcinoma: analysis of a large multicenter cohort (Radical Nephroureterectomy Outcomes (RaNeO) Research Consortium) 167
Conditional survival of patients with low-risk prostate cancer: Temporal changes in active surveillance permanence over time 165
Can we predict pathology without surgery? Weighing the added value of multiparametric MRI and whole prostate radiomics in integrative machine learning models 165
Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials 165
Radiomics in prostate cancer: an up-to-date review 165
Impact of Perioperative Immunonutrition on Complications in Patients Undergoing Radical Cystectomy: A Retrospective Analysis 163
Robot-assisted Partial Nephrectomy: 5-yr Oncological Outcomes at a Single European Tertiary Cancer Center 161
Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance 160
Uro-oncologic patient management during the COVID-19 pandemic: Survey findings from an Italian oncologic hub 159
Prognostic accuracy of prostate health index and urinary prostate cancer antigen 3 in predicting pathologic features after radical prostatectomy 158
Antioxidant treatment for oligoasthenoteratozoospermia and varicocele: a DBPC trial to evaluate the impact of age and body mass index 155
Microwave vs radiofrequency ablation for small renal masses: perioperative and oncological outcomes 154
Prostate Cancer Radiogenomics-From Imaging to Molecular Characterization 154
Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer 154
Progress in prostate cancer prevention 153
Molecular Characterization of Cancer Associated Fibroblasts in Prostate Cancer 152
Totale 22.530
Categoria #
all - tutte 106.229
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 106.229


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202183 0 0 0 0 0 0 0 0 0 0 0 83
2021/20221.496 90 84 54 98 166 125 68 113 140 120 82 356
2022/20232.008 244 175 143 177 149 308 153 123 298 36 148 54
2023/20245.183 101 117 95 128 384 211 814 718 357 652 790 816
2024/20258.026 737 750 633 547 325 513 414 580 445 641 772 1.669
2025/202623.465 2.003 2.225 4.268 2.212 1.581 1.113 2.008 1.186 2.204 1.262 2.589 814
Totale 43.682